Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helixor P infusion for cancer-related fatigue during standard therapy
2018-001596-20Phase 2Active
- Sponsor
- Helixor Heilmittel GmbH
- Start
- Aug 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of viscum album extract in breast cancer and non-small cell lung cancer (NSCLC), sponsored by Helixor Heilmittel GmbH. Primary endpoint: Change in total cancer-related fatigue score. Started Aug 2018; status: active.
02
Drugs
viscum album extract
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-001596-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001596-20.